Oncology drugs revenue Russia 2028

The revenue in the 'Oncology Drugs' segment of the pharmaceuticals market in Russia was forecast to continuously increase between 2024 and 2028 by in total 0.9 billion U.S. dollars (+66.18 percent). After the sixth consecutive increasing year, the indicator is estimated to reach 2.24 billion U.S. dollars and therefore a new peak in 2028.

Find further information concerning the revenue in the 'Vaccines' segment of the pharmaceuticals market in Argentina and the revenue in the 'Anti-Diabetes Drugs' segment of the pharmaceuticals market in Italy.

The Statista Market Insights cover a broad range of additional markets.

Revenue of oncology drugs in Russia from 2019 to 2028 (in billion U.S. dollars)

Characteristic	Revenue in billion U.S. dollars
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

More information

Supplementary notes

Data provided by Statista Market Insights are estimates.

The Oncology Drugs market covers drugs to treat cancer, including chemotherapy and immunotherapy. These therapies are used for solid tumors and hematologic cancer. The medications in this market are mainly physician-administered drugs.

Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Bristol-Myers Squibb, Roche, Merck & Co, Novartis, Johnson & Johnson

Citation formats